About TriAxia Health

Rare disease Data/Analytics as a Service
for Providers, Biopharmas, and Payers

 

TriAxia Health does not proactively contact job applicants who have not contacted us, and will never ask any applicant to install an application, pay a fee, or provide financial information as part of the application process.  If someone contacts you about a job claiming to represent TriAxia, they almost certainly do not represent the company.

OUR MISSION

At TriAxia Health, our mission is to improve health outcomes for patients living with rare diseases by enabling the selection and discovery of the most effective treatments for each patient.  We do so through collaboration across leading provider networks, the integration of clinical, molecular, and historic patient information, and the application of AI and Machine Learning to our combined clinical-molecular-claims-Rx data set.

Collaboration:
Since the number of patients at any given medical center, even one specializing in rare disease, is too small to develop a complete understanding of the disease (exacerbated by the tendency of rare diseases to have high hazard ratios), the TAH platform is used by multiple leading hospital systems (currently Mass General Brigham, Stanford, UPMC, Weill-Cornell and the University of Arizona/Banner Health), each of whom provides both quaternary and community care, so that the aggregation of their collective patient data (from their EMRs and disease-specific registries) provides the necessary combination of depth (number of patients) and breadth (variety of treatment approaches) necessary to understand their conditions.

Clinical & molecular patient information:
Since 80% of rare diseases have a genetic etiology, fully understanding these diseases to provide both the best treatments today and enable the search for new cures in the future requires the combination of clinical and molecular (genomic, proteomic, metabolomic) data. Supported by Illumina, TAH is combining cutting-edge molecular data tailored to a given rare disease with clinical data to provide a unique, in-depth understanding of each patient.

AI and Machine Learning:
Leveraging both cutting edge AI and traditional epidemiology, we develop models to help explain and predict variability of outcomes across patients, treatments, and rare diseases 

Historical Claims & Rx Data: The average rare disease patient takes 7.6 years to receive an accurate diagnosis.  We address this issue through a unique data partnership providing us with 12 years of proprietary prescriptions and health claims history on 92% of the US population

We are building a cloud-based, AI-powered rare disease patient management platform to store, analyze and capitalize on novel insights for payers, providers and life science companies who collaborate to help people with these diseases receive the best care.

We hope you’ll join us.

LEADERSHIP TEAM
SIMON KENNEDY
CEO / Founder
    • Senior Advisor, Bain & Company, ZappRx
    • Senior Advisor/Operations Partner Symphony Technology Group, a Private Equity firm
    • Executive Chair, Evidera (acquired by PPD 8/16); Director, SHS (acquired by PRA Health Sciences 8/17)
    • Senior Partner and Managing Director The Boston Consulting Group; Founder/ Global Leader BCG HCIT practice
    • Led the development of the Observational Medical Outcomes Partnership (OMOP) for BCG, PhRMA, FDA, and the NIH
    • Established the International Consortium for Health Outcomes Measurement (ICHOM) a JV between BCG, the Karolinska Institute and the Institute for Strategy and Competitiveness at Harvard
VLADIMIR I. VALTCHINOV, PhD
Vice President, Data and Analytics
    • Founding CTO for two successful-exit clinical informatics, decision support and RWE/AI analytics start-ups
    • Thought leader in multiple subject-matter areas related to data science, predictive analytics, machine learning, advanced statistics, bioinformatics, and genomics with over 45 peer reviewed publications.
    • Sub-areas Co-PI for federally sponsored research: i2b2, the National Center for Biomedical Computing Informatics for Integrating Biology and the Bedside, Medical Imaging Demonstration (MID) commissioned by US Congress
    • Co-founded a boutique IT consulting, custom software development and implementation, data science and analytics company
BENNETT LANE, MD, MS
Director, Health Startegy
    • Practicing emergency medicine physician and critical care transport medicine physician
    • Active, grant-supported researcher in health economics
    • Project Leader, Boston Consulting Group
    • Completed medical school at Harvard Medical School and graduate research training in Molecular Biophysics and Biochemistry at Yale University
J. MARC OVERHAGE, MD, PhD
Senior Advisor / Co-Founder
    • Chief Health Informatics Officer, Cerner & Siemens Healthcare
    • President & CEO, Indiana Health Information Exchange
    • Director of Medical Informatics, Regenstrief Institute
    • Director of Development, DOME software
    • Primary Investigator, Observational Medical Outcomes Partnership
    • Director Healthcare Information Management Systems Society (HiMSS), National Quality Forum, and  American Medical Informatics Association (AMIA); member HIT Standards Committee
SCIENTIFIC ADVISORY TEAM
JONATHAN WHITE, MD
Rare Disease Patient Advisor
    • EVP R&D, PatientsLikeMe
    • Former Corporate VP of Strategy and Product Development and a member of the Senior Leadership Team at IMS-Quintiles, where he launched products for rare diseases and for digital health care management
    • Former EVP of Research and Development and member, Executive Committee of Haemonetics, a manufacturer of blood diagnostics and services
    • Former SVP of Innovation and Chief Information Officer, and on the Executive Committee of Pfizer
    • Trained as a Neurosurgeon at the University of Cambridge
    • Dr. White is a Fellow of the Royal College of Surgeons and holds an MBA from INSEAD in France
TANYA MORENO, PhD
BioPharma Discovery Advisor
    • VP of Clinical Sciences, Research and Development in multiple clinical laboratories, technical expert in use of advanced genomic technologies for precision medicine
    • Published widely in peer-reviewed journals on consumer and clinical genomics research, inventor of novel genomic applications with multiple patents pending and granted
    • Trained in molecular genetics, developmental biology and neurobiology at the California Institute of Technology and the Salk Institute for Biological Studies
ROBERT EPSTEIN, MD
Senior Advisor
    • Former President, Medco Advanced Clinical Science and Research and CMO, Medco Health Solutions
    • Director at Illumina, Proteus, Fate Therapeutics, Veracyte and Mindstrong Health
    • Former elected President, International Society of Pharmacoeconomics and Outcomes Research (ISPOR)
    • Member Federal CDC EGAPP (Evaluation of Genomic Applications in Practice & Prevention) Stakeholder Committee and the AHRQ CERT (Centers for Education and Research on Therapeutics) Committee
    • Has published more than 50 peer-reviewed medical articles and book chapters and serves as a reviewer for several influential medical journals

 

Pulmonary Rare Disease Scientific Advisory Board
    • Roham Zamanian, MD  |  SAB Chair
      Stanford Medicine
    • Aaron Waxman, MD, PhD
      Mass General Brigham
    • Michael Risbano, MD
      UPMC
    • Evelyn Horn, MD
      Weill Cornell Medicine
    • Franz Rischard, MD
      Banner Health
PUBLICATIONS

TAH ATS Poster 2021

CHEST Annual Meeting Poster 2023